Kairos Pharma Ltd. (NYSE American: KAPA) announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. The partnership aims to address a significant unmet need in advanced prostate cancer, where treatment resistance often limits therapeutic options.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. In interim Phase 2 data previously reported by the company, ENV-105 demonstrated a median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.
The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have shown that ENV-105 can re-sensitize tumors to radiation, and Kairos management believes the combination could provide a more durable treatment option for patients with advanced prostate cancer.
Prostate cancer is one of the most common cancers in men, and metastatic castration-resistant prostate cancer is an advanced stage with limited treatment options. The development of therapies that can overcome resistance is critical for improving patient outcomes. If successful, this combination could offer a new approach for patients who have progressed on standard therapies.
Kairos Pharma, based in Los Angeles, California, focuses on oncology therapeutics using structural biology to overcome drug resistance and immune suppression. The company’s lead candidate, ENV-105, targets CD105, identified as a key driver of resistance and relapse. ENV-105 is also in a Phase 1 trial for non-small cell lung cancer. It has not yet been approved by the FDA or any other regulator.
For more information, visit the company’s newsroom at https://ibn.fm/KAPA.
